Publications

Publications
  1. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC Jr. Clin Cancer Res. 2017, 23(8), 1945-1954. More Details..
  2. SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival. Maxfield KE, Macion J, Vankayalapati H, Whitehurst AW. Mol Cell Biol. 2016, 36 (24), 3048-3057. More Details..
  3. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Bon, H, Wadhwa, K, Schreiner, A, Osborne, M, Carroll, T, Ramos-Montoya, A, Ross-Adams, H, Visser, M, Hoffmann, R, Ahmed, A. A, Neal, D. E, Mills, I. G. Mol Cancer Res, 2015, 13(4), 620-635. More Details..
  4. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. Lombardi M. S, Gilliéron, C, Dietrich D2, Gabay, C. J Leukoc Biol, 2015, 99, 1-11. More Details..